Atara Biotherapeutics, Inc. (ATRA) vs Neumora Therapeutics, Inc. Common Stock (NMRA)

A side-by-side comparison of Atara Biotherapeutics, Inc. and Neumora Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Atara Biotherapeutics, Inc. logo
ATRA
Atara Biotherapeutics, Inc.
$87M
$9.70HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
Neumora Therapeutics, Inc. Common Stock logo
NMRA
Neumora Therapeutics, Inc. Common Stock
$89M
$0.48HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT

Total return — ATRA vs NMRA

growth of $100 · dividends reinvested · last 3y
ATRA -75.9% (-37.8%/yr)NMRA -96.8% (-68.1%/yr)ATRA compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202420252026$24$3
ATRA NMRA

ATRA vs NMRA: by the numbers

  • •NMRA is the larger company ($89M vs $87M market cap).
  • •Both run net losses; NMRA's is the smaller (0.00% vs -269.42% net margin).

Metrics side by side

Valuation

MetricATRANMRA
P/S ratio14.11N/A
P/B ratioN/A2.01

Profitability

MetricATRANMRA
Gross margin82.44%0.00%
Operating margin29.69%0.00%
Net margin-269.42%0.00%
ROEN/A-477.87%
ROIC-100.35%-216.05%

Growth (annualized)

MetricATRANMRA
Revenue CAGR (5Y)56.10%N/A
Total return CAGR (5Y)-53.60%N/A

Go deeper

Full ATRA analysisFull NMRA analysisInteractive comparison tool

Dig into the metrics

Atara Biotherapeutics ROENeumora Therapeutics, Inc. Common Stock ROEAtara Biotherapeutics operating marginNeumora Therapeutics, Inc. Common Stock operating marginAtara Biotherapeutics revenue growthNeumora Therapeutics, Inc. Common Stock revenue growthAtara Biotherapeutics free cash flowNeumora Therapeutics, Inc. Common Stock free cash flow

Atara Biotherapeutics & Neumora Therapeutics, Inc. Common Stock appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.